1. Home
  2. Research
  3. Centers & Labs
  4. RIKEN Center for Advanced Intelligence Project
  5. Goal-Oriented Technology Research Group

RIKEN Center for Advanced Intelligence Project Medical-risk Avoidance based on iPS Cells Team

Team Leader: Naonori Ueda (D.Eng.)

Research Summary

Naonori  Ueda(D.Eng.)

In cooperation with the iPS cell research institute (CiRA) of Kyoto university, by using AI and iPS cell technologies jointly, this team will research and develop technologies for predicting Altzheimer's disease risk which is becoming social urgent matter. Moreover, we will conduct research develop technologies to ensure the safety of iPS cells themselves. The former results will improve the possibility of risk prediction of Altzhimer's disease with solution, and the latter will enable the stock of high quality iPS cells for regenerative medicine.

Main Research Fields

  • Clinical Medicine

Related Research Fields

  • Computer Science
  • Geosciences

Research Subjects

  • Identification of Alzheimer's risk control drug
  • Genome abnormality verification technology
  • Abnormality prediction technology for iPS cells and cells derived from iPS cells

Selected Publications

Papers with an asterisk(*) are based on research conducted outside of RIKEN.

  • 1.*Imamura, K., Izumi, Y., Watanabe, A., Tsukita, K., Woltjen, K., Yamamoto, T., Hotta, A., Kondo, H., Kitaoka, S., Ohta, A., Tanaka, A., Watanabe, D., Morita, M., Takuma, H., Tamaoka, A., Kunath, T., Wray, S., Furuya, H., Era, T., Makioka, K., Okamoto, K., Fujisawa, T., Nishitoh, H., Homma, K., Ichijo, H., Julien, J., Obata, N., Hosokawa, M., Akiyama, H., Kaneko, S., Ayaki, T., Ito, H., Kaji, R., Takahashi, R., Yamanaka, S., Inoue, H.:
    “The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis,”
    Science Translational Medicine, 9(391), eaaf3962 ,2017.
  • 2.*Shi, Y., Inoue, H., Wu, J. C., Yamanaka, S.:
    “Induced pluripotent stem cell technology: a decade of progress,”
    Nature Reviews Drug Discovery, 16, 115-130 (2017)
  • 3.*Ohara, R., Imamura, K., Morii, F., Egawa, N., Tsukita, K., Enami, T., Shibukawa, R., Mizuno, T., Nakagawa, M., Inoue, H.: “Modeling drug-induced neuropathy using human iPSCs for predictive toxicology,”
    Clinical Pharmacology & Therapeutics, 101(6), 754-762,2017.
  • 4.*Imamura, K., Sahara, N., Kanaan, N. M., Tsukita, K., Kondo, T., Kutoku, Y., Ohsawa, Y., Sunada, Y., Kawakami, K., Hotta, A., Yawata, S., Watanabe, D., Hasegawa, M., Trojanowski, J. Q., Lee, V. M., Suhara, T., Higuchi, M., Inoue, H.:
    “Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons,”
    Scientific Reports, 6, 34904,2016.
  • 5.*Hanatani, T., and Takasu, N.:
    “iPS cell stock project,”
    BIO Clinica, 31(11), 18-22, 2016.
  • 6.*Hanatani, T., and Takasu, N.:
    “Present and Future of an iPS Cell Stock for Regenerative Medicine,”
    Rinsho Byori, 65(2), 160-166,2017.

Related Links

Lab Members

Principal investigator

Naonori Ueda
Team Leader

Core members

Ichigaku Takigawa
Research Scientist
Ayako Nagahashi
Technical Scientist
Takako Enami
Technical Staff I
Yuki Matsubayashi
Technical Staff I
Ikuyo Inoue
Technical Staff I

Contact Information

Center for iPS Cell Research and Application, Kyoto University

Email: naonori.ueda [at] riken.jp

Top